PARP1 and colonic neoplasm: Given that inhibition of drug efflux channels by verapamil was previously shown to decrease the survival of MRN-deficient colon cancer cells (HCT116 cells) treated with a PARP inhibitor [52], we also tested whether verapamil would potentiate the mitotic phenotypes caused by olaparib in different cell lines (Figure 6).